|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||7.33 - 7.56|
|52 Week Range||5.70 - 8.11|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 22, 2019 - Mar 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DEER PARK, Ill., March 25, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
Eton Pharmaceuticals, Inc. (ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process. DS-200 was previously granted Fast Track Designation by the FDA. “The commencement of the NDA submission process for DS-200 marks an important milestone for Eton as we continue to progress DS-200 and our broader late stage pipeline with a new total of four products applications submitted to the FDA,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals.
DEER PARK, Ill., Feb. 21, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind EM-100 Has Been Submitted to the FDA for Review LAVAL, Quebec and DEER PARK, Ill. , Feb. 19, 2019 /PRNewswire/ -- Bausch ...
Eton Pharmaceuticals, Inc. (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a Swiss-based pharmaceutical company, to obtain U.S. marketing rights to two injectable product candidates. With the addition of these product candidates, Eton now has three product candidates submitted with the FDA and expects to submit two additional NDAs by the third quarter of 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week peaks Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 24) Amneal ...
ET-104’s active ingredient is approved and marketed in an oral solid formulation, but the active ingredient is not approved by the U.S. Food and Drug Administration (FDA) in liquid form. Presently, patients requiring liquid formulations of the active ingredient are reliant on compounded products.
Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill., Dec. 20, 2018 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a.
Imprimis Pharmaceuticals, Inc. (IMMY) today announced that it ranked 88th on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Winners were selected based on percentage fiscal year revenue growth from 2014 to 2017, and Imprimis grew 1,513% during this period. “Congratulations to the Deloitte 2018 Technology Fast 500 winners on this impressive achievement,” said Sandra Shirai, vice chairman, Deloitte LLP, and U.S. technology, media and telecommunications leader.
Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of its common stock at a public offering price of $6.00 per share. All of the shares are being offered by Eton. In addition, Eton has granted the underwriter a 45-day option to purchase an additional 540,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates are expected, not confirmed, at time of publication. BankFlorida (BFL) will issue 6.2 million shares between ...